Vesigel is a small molecule commercialized by UroGen Pharma, with a leading Phase III program in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to Globaldata, it is involved in 7 clinical trials, of which 6 were completed, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Vesigel’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Vesigel is expected to reach an annual total of $164 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Vesigel Overview
VesiGel is under development for the treatment of low-grade intermediate risk non muscle invasive bladder cancer (NMIBC). VesiGel is a sustained release formulation of a high dose mitomycin C. It is administered through intravesical route as a solution. It acts by targeting DNA. It is developed based on reverse thermally triggered hydrogel (RTGel) platform technology.
UroGen Pharma Overview
UroGen Pharma, formerly TheraCoat, is a biotechnology company that develops and commercializes novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs and Jelmyto for pyelocalyceal solution. The company pipeline products include UGN-102, which treats non-muscle invasive urothelial cancer; UGN-301 for High-grade non-muscle-invasive bladder cancer. UroGen Pharma is headquartered in Ra Anana, Israel.
The company reported revenues of (US Dollars) US$82.7 million for the fiscal year ended December 2023 (FY2023), an increase of 28.5% over FY2022. The operating loss of the company was US$65.5 million in FY2023, compared to an operating loss of US$79 million in FY2022. The net loss of the company was US$102.2 million in FY2023, compared to a net loss of US$109.8 million in FY2022.
For a complete picture of Vesigel’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
